viewAlliance Pharma PLC

Alliance Pharma PLC well placed for future opportunities, says chief

John Dawson, chief executive of Alliance Pharma PLC (LON:APH), tells Proactive Investors that the recent acquisition of the Sinclair Healthcare Products Business has had a “transformational” effect on the business.

He says the deal doubles Alliance’s sales, profits, and market capitalisation, adding that the company is now “in a place that we can bid for other opportunities in the future”.

Dawson goes on to say it also gives the company a “much stronger presence across the top five EU countries,” as well as in China and South East Asia.

Alliance reported robust final statement for the year ended 31 December 2015 on Thursday, with revenue up 11% to £48.3mln, compared to £43.5mln the previous year. 

Quick facts: Alliance Pharma PLC

Price: 70.2 GBX

Market: AIM
Market Cap: £372.81 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Alliance Pharma PLC named herein, including the promotion by the Company of Alliance Pharma PLC in any Content on the Site, the Company...



'It's never been so busy and exciting', says Alliance Pharma PLC CEO

Alliance Pharma plc (LON:APH) said revenues had more than doubled and trading profits for the year to the end of December were in line with City forecasts as it provided investors with a progress report. The speciality pharma company said it expects sales to be £97.5mln - up from £48.3mln...

on 24/1/17

2 min read